References
Burisch J, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013 May;7(4):322-37.
Stalgis C, Deepak P, Mehandru S, et al. Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. Gastroenterology. 2021 Aug;161(2):394-399. doi: 10.1053/j.gastro.2021.04.068.
Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160:1570–1583.
Ungaro RC, Aggarwal S, Topaloglu O, et al. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease. Aliment Pharmacol Ther 2020; 51: 831–842.
Feng Z, Kang G, Wang J, et al. Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies. Biomed Pharmacother. 2023 Feb;158:114174. doi: 10.1016/j.biopha.2022.114174.
Atreya R and Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2018; 3: 790–802.
Borg-Bartolo SP, Boyapati RK, Satsangi J, et al. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020 Jan 28;9:F1000 Faculty Rev-54. doi: 10.12688/f1000research.20928.1.
Syed S, Boland BS, Bourke LT, et al. Challenges in IBD Research 2024: Precision Medicine. Inflamm Bowel Dis. 2024 May 23;30(Suppl 2):S39-S54. doi: 10.1093/ibd/izae084.
Noor NM, Sousa P, Paul S, et al. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis. 2022 Aug 1;28(8):1254-1264. doi: 10.1093/ibd/izab228.
Torres J, Halfvarson J, Rodríguez-Lago I, et al. Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Prediction and Prevention of Inflammatory Bowel Disease. J Crohns Colitis. 2021 Sep 25;15(9):1443-1454. doi: 10.1093/ecco-jcc/jjab048.
Colombel JF, Sandborn WJ, Reinisch W, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492.
Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392-400.e3.
Boleto G, Kanagaratnam L, Dramé M, et al. Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2019;49(1):35-42.
Hirten RP, Iacucci M, Shah S, et al. Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders. Clin Gastroenterol Hepatol 2018; 16:1374–1384.
Solitano V, Ma C, Hanžel J, et al. Advanced Combination Treatment With Biologic Agents and Novel Small Molecule Drugs for Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2023 May;19(5):251-263.
Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007;13:2–11.
Gold SL, Steinlauf AF. Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature, Gastroenterol. Hepatol. 17 (9) (2021) 406–414.
Hirten R, Longman RS, Bosworth BP, et al. Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn’s Disease. Am J Gastroenterol. 2015;110(12):1737– 1738.
Buer LCT, Høivik ML, Warren DJ, et al. Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. Inflamm Bowel Dis. 2018;24(5):997–1004. https://doi.org/10.1093/ibd/izx110.
Glassner K, Oglat A, Duran A et al. The use of combination biological or small molecule therapy in inflammatory bowel dis- ease: A retrospective cohort study. J Dig Dis. 2020;21(5):264– 271. https://doi.org/10.1111/1751-2980.12867.
Yang E, Panaccione N, Whitmire N, et al. Efficacy and safety of simultaneous treatment with two biologic medica- tions in refractory Crohn's disease. Aliment Pharmacol Ther. 2020;51(11):1031–1038. https://doi.org/10.1111/apt.15719.
Dolinger MT, Spencer EA, Lai J, et al. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 Jul 27;27(8):1210-1214. doi: 10.1093/ibd/izaa277.
Llano EM, Shrestha S, Burstein E, et al. Favorable outcomes combining vedolizumab with other biologics or tofacitinib for treatment of inflammatory bowel disease. Crohn’s Colitis 360. 2021;3(3):otab030.
Alayo QA, Khatiwada A, Patel A, et al. Effectiveness and safety of combining tofacitinib with a biologic in patients with re- fractory inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27(10):1698–1702.
Kwapisz L, Raffals LE, Bruining DH et al. Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Ter- tiary Care Center. Clin Gastroenterol Hepatol. 2021;19(3):616– 617. https://doi.org/10.1016/j.cgh.2020.02.017.
Goessens L, Colombel J, Outtier A, et al. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immunemediated inflammatory diseases: a European retrospective observational study. United Eur Gastroenterol J 2021; 9:1136–1147.
Lee SD, Singla A, Harper J, et al. Safety and efficacy of tofacitinib in combination with biologic therapy for refractory Crohn’s disease. Inflamm Bowel Dis. 2022;28(2):309–313.
Guillo L, Flachaire B, Avouac J, et al; COMBIO Study Group. Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study. Dig Liver Dis. 2023 Jan;55(1):61-68. doi: 10.1016/j.dld.2022.07.012.
Ribaldone DG, Pellicano R, Vernero M, et al. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Scand J Gastroenterol 2019;54:407–413.
Privitera G, Pugliese D, Lopetuso LR, et al. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol. 2021 Apr 27;14:17562848211006669. doi: 10.1177/17562848211006669.
Berinstein EM, Sheehan JL, Jacob J, et al. Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature. Dig Dis Sci 2023; 68: 2604-2623. doi: 10.1007/s10620-023-07837-0.
Ahmed W, Galati J, Kumar A, et al. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2022;20:e361–e379.
Alayo QA, Fenster M, Altayar O, et al. Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. Crohns Colitis 360 2022; 4: otac002. doi: 10.1093/crocol/otac002.
Feagan BG, Sands BE, Sandborn WJ, et al; VEGA Study Group. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7.
J Perrigoue, L Muniz-Bongers, L Ong, et al, VEGA, P328 In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel Disease, Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Page i348, https://doi.org/10.1093/ecco-jcc/jjab232.455.